Physician profile
Daniel J Howley
NPI 1902885502
$5,498.45
in general payments reported to CMS, 2019-2025
38 companies · $871 in 2025
The $871 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $386 · 2020: $467 · 2021: $448 · 2022: $1,107 · 2023: $1,032 · 2024: $1,187 · 2025: $871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,090.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,089.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $634.57 | 2019-2025 | Briviact, Nayzilam |
| Sk Life Science, INC. | $427.59 | 2020-2025 | |
| Biogen, INC. | $426.64 | 2021-2025 | Vumerity, Tysabri |
| Lilly USA, LLC | $405.01 | 2019-2025 | Kisunla, Emgality, Amyvid |
| Abbvie INC. | $402.61 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $353.96 | 2019-2025 | |
| Lundbeck LLC | $263.76 | 2022-2025 | Vyepti |
| Celgene Corporation | $254.59 | 2021-2024 | Zeposia |
| Alexion Pharmaceuticals, INC. | $251.17 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $204.83 | 2022-2025 | Ingrezza, Ongentys |
| Emd Serono, INC. | $189.41 | 2019-2025 | Mavenclad |
| Amgen INC. | $184.02 | 2020-2022 | |
| Eisai INC. | $173.10 | 2023-2025 | |
| Pfizer INC. | $168.34 | 2023-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $131.35 | 2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Howley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.